cGAP-PNA Multivalent Ligand Display at the Nanoscale


Scientists at the NIH are developing new types of peptide nucleic acids (PNAs) that maintain aqueous solubility at longer lengths. This new type of PNA is called “cGAP-PNA” because it contains a sequence complementary to the L-PNA sequence, which is a PNA with one or more gamma-sidechains that displays a ligand. The investigators have synthesized cGAP-PNAs that are 60 nucleobases long that can support the assembly of 5 complementary L-PNAs (each with 12 nucleobases) that bear specific ligands. This platform can replace more traditional multivalent scaffolds, such as dendrimers and gold nanoparticles.



Potential Commercial Applications: Competitive Advantages:
  • Multivalent ligand display.
 
  • Decreased hydrophobicity
  • Increased water solubility
  • Can be used at very long lengths
  • More stable and resistant to degradation than existing PNAs


Development Stage:
  • Early-stage
  • In vitro data available


Related Invention(s):
E-308-2006/3
E-129-2010/0


Inventors:

Daniel Appella (NIDDK)  ➽ more inventions...

Ethan Englund (NIDDK)  ➽ more inventions...

Andrew Dix (NIDDK)  ➽ more inventions...


Intellectual Property:
US Application No. 15/112,981
US Application No. 61/929,893
PCT Application No. PCT/US2015/011730

Publications:

Dix A, et al.

PMID 25116377

Collaboration Opportunity:

The National Institute of Diabetes and Digestive and Kidney Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize this technology. For collaboration opportunities, please contact Marguerite Miller at Marguerite.Miller@nih.gov or 301-496-9003.




Licensing Contact:
Marguerite Miller, M.B.A.
Email: millermarg@mail.nih.gov
Phone: 301-496-9003

OTT Reference No: E-761-2013/0
Updated: Apr 18, 2017